|
U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institute of Allergy and Infectious Diseases (NIAID) <https://www.niaid.nih.gov/> For Immediate Release: Tuesday, September 17, 2024 CONTACT: NIAID News & Science Writing Branch, (301) 402-1663, <email:niaidnews@xxxxxxxxxxxxx> MEDIA ADVISORY NIH RELEASES MPOX RESEARCH AGENDA Plan will advance knowledge of virus biology to improve detection, treatment and prevention WHAT: As part of the U.S. government response to the current mpox outbreak <https://www.cdc.gov/poxvirus/mpox/outbreak/2023-drc.html>, the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has
released an update on its priorities for mpox research <https://www.niaid.nih.gov/sites/default/files/2024-09-06-niaid-mpox-research-summary-final_508.docx>. The NIAID mpox research agenda focuses on four key objectives: increasing knowledge about the biology
of all clades—also known as strains—of the virus that causes mpox, including how the virus is transmitted and how people’s immune systems respond to it; evaluating dosing regimens of current vaccines to stretch the vaccine supply and developing novel vaccine
concepts; advancing existing and novel treatments, including antivirals and monoclonal antibodies; and supporting strategies for detecting the virus to facilitate clinical care and epidemiological surveillance.
The first human case of mpox was recorded in 1970 in the Democratic Republic of the Congo. The disease is endemic in central and western Africa. Two types of the virus that causes mpox have been identified: Clade I is endemic in Central
Africa and can cause severe illness. Clade II, endemic in West Africa, tends to result in milder illness and caused the global mpox outbreak in 2022 <https://www.cdc.gov/poxvirus/mpox/outbreak/2022-ongoing-global.html>. People with compromised immune systems,
children, and people who are pregnant are especially vulnerable to severe mpox regardless of the virus clade.
NIAID continues to collaborate closely with U.S. and international partners to reduce the impact of the current mpox outbreak and safeguard public health globally. NIAID will leverage both its domestic and international research infrastructures
to achieve the Institute’s research objectives. NIAID Research Agenda for 2024 Mpox – September 2024 <https://www.niaid.nih.gov/sites/default/files/2024-09-06-niaid-mpox-research-summary-final_508.docx> WHO: NIAID Director Jeanne M. Marrazzo, M.D., M.P.H., is available to discuss the institute’s mpox research agenda. View a video <https://youtu.be/1-wHiNdj2Tg>of her summarizing the priorities. Access the audio-described version of the video
<https://youtu.be/TpYtyGB-yuU>. NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses.
News releases, fact sheets and other NIAID-related materials are available on the NIAID website<https://www.niaid.nih.gov/>. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting
and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This NIH News Release is available online at: <https://www.nih.gov/news-events/news-releases/nih-releases-mpox-research-agenda> To subscribe (or unsubscribe) from NIH News Release mailings, go to <http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>. If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>. |
